Live Breaking News & Updates on Aurinia Pharmaceuticals Inc Stock Exchange

Stay updated with breaking news from Aurinia pharmaceuticals inc stock exchange. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy

LUPKYNIS® achieved significantly earlier reductions in UPCR and significantly higher renal response rates in lupus nephritis patients with high proteinuria, compared to patients treated with. | June 20, 2023 ....

United States , Wei Ky , Aurinia Pharmaceuticals , Meeting Of The European Renal Association , Aurinia Pharmaceuticals Inc , Annual Meeting , European Renal Association , Red Cell Aplasia , Drug Interactions , Moderate Hepatic Impairment , Prescribing Information , Boxed Warning , Medication Guide , European Renal Associate Annual Meeting , Aurinia Pharmaceuticals Inc Stock Exchange , Press Release , Reated Auph Ca05156v1022 ,

Aurinia Pharmaceuticals : Jefferies Healthcare Conference June 2023

Corporate Presentation

Jefferies Healthcare Conference June 8, 2023

Cautionary statement. | June 8, 2023 ....

United States , Exchange Commission Electronic Document Gathering , Annual Report , Canadian Securities Administrator System , Electronic Document Analysis , Exchange Commission , Electronic Document Gathering , Retrieval System , Aurinia Pharmaceuticals Inc Stock Exchange , Press Release , Autionary Auph Ca05156v1022 ,

Aurinia Pharmaceuticals Inc. - LUPKYNIS Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone

EDMONTON - Aurinia Pharmaceuticals Inc. today announced the results of a post-hoc, pooled analysis of the Phase 2 AURA-LV and Phase 3 AURORA 1 studies, which found that LUPKYNIS with. | June 2, 2023 ....

United States , Greg Keenan , Emily Littlejohn , Andrea Christopher , Aurinia Pharmaceuticals Inc , European Congress , Aurinia Pharmaceuticals , Cleveland Clinic Main Campus , Immunologic Disease , Chief Medical Officer , Red Cell Aplasia , Drug Interactions , Moderate Hepatic Impairment , News Publishing , Aurinia Pharmaceuticals Inc Stock Exchange , Press Release , Upkynis Auph Ca05156v1022 ,

LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone

Aurinia Pharmaceuticals Inc. today announced the results of a post-hoc, pooled analysis of the Phase 2 AURA-LV and Phase 3 AURORA 1 studies, which found that LUPKYNIS® with mycophenolate. | June 1, 2023 ....

United States , Emily Littlejohn , Greg Keenan , Aurinia Pharmaceuticals , European Congress , Aurinia Pharmaceuticals Inc , Cleveland Clinic Main Campus , Immunologic Disease , Chief Medical Officer , Red Cell Aplasia , Drug Interactions , Moderate Hepatic Impairment , Prescribing Information , Boxed Warning , Medication Guide , Aurinia Pharmaceuticals Inc Stock Exchange , Press Release , Ith Auph Ca05156v1022 ,

Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees

Aurinia Pharmaceuticals Inc. today announced the filing of a registration statement on Form S-8 with the United States Securities and Exchange Commission .

Under U.S. federal securities laws,. | May 26, 2023 ....

United States , Aurinia Pharmaceuticals Inc , Aurinia Pharmaceuticals , Exchange Commission , United States Securities , Securities Act , Nasdaq Listing Rule , Aurinia Pharmaceuticals Inc Stock Exchange , Press Release , Ecurities Auph Ca05156v1022 ,